The breast cancer screening market in the European region is estimated to be growing at a CAGR of 4.41% from 2021 to 2026 and worth USD 518.11 million in 2021 and USD 642.94 million by 2026.
Breast cancer is the second most common cancer in women across the globe, with over 2 million new cases detected in 2019. The increasing incidence of breast cancer, the presence of leading players in the European breast cancer screening market, and solid research and development are significant factors driving the market's growth. Approximately 58,000 women and 380 men are diagnosed with breast cancer each year in the UK. In Englan, nearly 47,000 people are diagnosed with breast cancer each year. In Scotland, around 4,800 people are diagnosed with breast cancer each year. In Wales, approximately 2,900 people are diagnosed with breast cancer each year. According to EUROPA DONNA, the European Coalition Against Breast Cancer, breast cancer is the most common cancer among women in the European region with a prevalence of 565,500 in 2019, and 1 in 8 women in the European nations will develop breast cancer before the age of 85. Breast cancer, therefore, affects many women during their peak years, which is likely to drive market growth during the forecast period.
The increasing number of breast cancer cases is mainly due to unhealthy habits like smoking, unhealthy diet or infections, and positive family history. This increases the demand for gold standard mammograms, while blood and laboratory tests and other diagnostic imaging tests are also gaining popularity. The Globocan report indicates that in 2019, 32,900 new breast cancer cases were discovered, and 6,500 deaths from breast cancer were reported in Spain. Due to this increase in breast cancer cases in Spain, there is an increasing need for routine screening and advancement in technologies. Several local governments and other healthcare organizations around Europe are conducting free breast screening camps and education to increase the prognosis for breast cancer patients with early diagnosis.
However, the high cost associated with breast cancer screening is slowing the growth of the market. In addition, certain risks associated with using X-ray machines and radiations may limit the uptake of breast cancer screening procedures in the region.
This research report on the European breast cancer screening market has been segmented and sub-segmented into the following categories.
Germany dominated the European breast cancer screening market and accounted for the largest revenue share of 29% in 2020. According to the Globocan report, the total number of breast cancer cases in Germany recorded was approximately 72,000 in 2019, and around 19,400 breast cancer deaths have been reported. Breast cancer is one of the most common types of cancer in Germany. The significant factors contributing to the dominance of this region are the presence of substantial players coupled with advanced research and development in diagnostic and screening techniques, high patient awareness, and favorable reimbursement policies.
In high-income European countries, such as Denmark, breast cancer mortality has declined over the past 20 to 20 years, from a rate of 55 per 100,000 in early 1960 to a steady decline of 35 per 100,000 in 2017.
In the United Kingdom, the regional market is expected to experience the highest CAGR during the forecast period owing to the increasing incidence of breast cancer, improving reimbursement guidelines, well-developed healthcare infrastructure, and the adoption of the latest technologies. According to statistics from Cancer Research UK, there were 55,200 new cases of breast cancer and 11,450 cancer deaths between 2016 and 2018. In addition, statistics state that nearly 152 new breast cancer cases are diagnosed in women every day. Although according to cancer research UK, Breast cancer in men is not as common in the UK, there were around 392 new cases in 2018.
KEY MARKET PARTICIPANTS:
Abbott Laboratories, Myriad Genetics Inc., Hologic Inc., Koninklijke Philips N.V., Fujifilm Holdings Corporation, GE Healthcare, Thermo Fischer Scientific Inc., Siemens AG, NanoString Technologies Inc., C. R. Bard Inc., Gamma Medica Inc., Aurora Imaging Technology Inc., Leica Biosystems Nussloch GmbH, bioTheranostics Inc., Bio-Rad Laboratories Inc., Illumina Inc., Biocept Inc., Epigenomics AG, AstraZeneca plc and Quest Diagnostics Incorporated are predicted to account for the majority of the share in the European breast cancer screening market during the forecast period.